Daporinad (FK866, APO866)

Name: Daporinad (FK866, APO866)
Brand: Selleck Chemicals
SKU: S2799
Rating: 5 (29 reviews)

For research use only.

Catalog No.S2799

29 publications

Daporinad (FK866, APO866) Chemical Structure

CAS No. 658084-64-1

Daporinad (FK866, APO866) effectively inhibits nicotinamide phosphoribosyltransferase (NMPRTase; Nampt) with IC50 of 0.09 nM in a cell-free assay. Daporinad (FK866, APO866) triggers autophagy. Phase 1/2.

Selleck's Daporinad (FK866, APO866) has been cited by 29 publications

Cell Metab, 2020, 31(3):564-579

PubMed: 32130883 ( click the link to review the publication )

Cell, 2019, 36(2):179-193

PubMed: 28162770 ( click the link to review the publication )

Cancer Cell, 2019, 36(2):179-193

PubMed: 31378681 ( click the link to review the publication )

Nat Biotechnol, 2017, 35(5):463-474

PubMed: 28319085 ( click the link to review the publication )

Cancer Discov, 2016, 6(7):727-39

PubMed: 27231123 ( click the link to review the publication )

Mol Ther, 2020, S1525-0016(20)30482-2

PubMed: 33002419 ( click the link to review the publication )

Mol Ther Nucleic Acids, 2020, 1;20:801-811

PubMed: 32438315 ( click the link to review the publication )

Front Cell Dev Biol, 2020, 17;8:191

PubMed: 32363189 ( click the link to review the publication )

Oxid Med Cell Longev, 2020, 2020:7308386

PubMed: 33149812 ( click the link to review the publication )

Mol Cancer Res, 2020, 10.1158/1541-7786.MCR-19-0669

PubMed: 32238439 ( click the link to review the publication )

Cell Microbiol, 2020, 22(1):e13115

PubMed: 31509891 ( click the link to review the publication )

Toxicol In Vitro, 2020, 65:104808

PubMed: 32087266 ( click the link to review the publication )

Cell Commun Signal, 2020, 18(1):16

PubMed: 32005247 ( click the link to review the publication )

Leukemia, 2020, 10.1038/s41375-019-0692-5

PubMed: 31896781 ( click the link to review the publication )

Nat Commun, 2019, 10(1):3790

PubMed: 31439867 ( click the link to review the publication )

Cancers (Basel), 2019, 11(12)

PubMed: 31795447 ( click the link to review the publication )

J Cell Physiol, 2019, 10.1002/jcp.28910

PubMed: 31141164 ( click the link to review the publication )

Life Sci, 2019, 225:20-28

PubMed: 30928408 ( click the link to review the publication )

Mol Psychiatry, 2018, 10.1038/s41380-018-0061-1

PubMed: 29728703 ( click the link to review the publication )

Nat Commun, 2018, 9(1):502

PubMed: 29402884 ( click the link to review the publication )

Cell chemical biology, 2018, 10.1016/j.chembiol.2017.12.008

PubMed: 29307841 ( click the link to review the publication )

Cell Physiol Biochem, 2018, 49(6):2463-2482

PubMed: 30261504 ( click the link to review the publication )

J Cell Physiol, 2018, 233(9):7402-7414

PubMed: 29663373 ( click the link to review the publication )

Neural Plast, 2017, 2017:7019803

PubMed: 28656112 ( click the link to review the publication )
Cancer Lett, 2016, 379(1):1-11

PubMed: 27233476 ( click the link to review the publication )

Drug Des Devel Ther, 2015, 9:1555-84

PubMed: 25792811 ( click the link to review the publication )

Drug Des Devel Ther, 2015, 10.2147/DDDT.S75976

PubMed: ( click the link to review the publication )

Mol Endocrinol, 2014, 28(3):395-405

PubMed: 24438340 ( click the link to review the publication )

PLoS One, 2014, 9(10):e111146

PubMed: 25343454 ( click the link to review the publication )

Purity & Quality Control

Choose Selective Transferase Inhibitors

Biological Activity

Description

Targets

NMPRTase ^[5]
(Cell-free assay)

0.4 nM(Ki)

In vitro

APO866 at low concentrations ranging from 0.09-27 nM induces dose-dependent cytotoxicity in 41 hematologic malignant cells including acute myeloid leukemia [AML], acute lymphoblastic leukemia [ALL], mantle cell lymphoma [MCL], chronic lymphocytic leukemia [CLL], and T-cell lymphoma. APO866 at low concentrations ranging from 0-10 nM induces cell death, this effect is independent of caspase activation but is associated with depolarization of mitochondrial membrane. APO866 at concentrations ranging from 0-10 nM dose-dependently induces depletion of intracellular NAD and ATP contents and cell death in various hematologic cancer cells. ^[1] APO866 at concentration of 10 nM inhibits PBEF-induced secretion of MMP-3, CCL2, and CXCL8 in HFFF2 cells. ^[2]

Cell Data

Cell Lines	Assay Type	Concentration	Incubation Time	Activity Description	PMID
SH-SY5Y	MUjDfZRwfG:6aXPpeJkh[XO\|YYm=			NY\rTZJpS3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hW0hvU2m1XUBk\WyuczDhd5Nme3OnZDDhd{Bz\WS3Y4Tpc44hd2ZidH;0ZYwh[2WubIXsZZIhVkGGKGCpJIxmfmWuLDDJR\|UxKD1iMD6wNFA2KM7:TT6=	M2n1eFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF7OU[xNVg{Lz5zOUm2NVE5OzxxYU6=
SH-SY5Y	NUTU[HVqS3m2b4TvfIlkcXS7IHHzd4F6		MWm0PEBpenN?	M2i5cmN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJHNJNVO\NWmgZ4VtdHNiYYPz[ZN{\WRiYYOgZ4VtdCC4aXHibYxqfHliYX\0[ZIhPDhiaILzJIJ6KE2WVDDhd5NigSxiSVO1NEA:KDBwMECxO{DPxE1w	NXK2bGFWRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUm5OlEyQDNpPkG5PVYyOTh\|PD;hQi=>
HT1080	MXXDfZRwfG:6aXPpeJkh[XO\|YYm=		MXe2JIRigXN?	NXLVbllHS3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hUFRzMEiwJINmdGy\|IHHmeIVzKDZiZHH5d{BjgSCVUlKgZZN{[XluIFnDOVAhRSByLkG2JO69VS5?	MVK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOTN\|MECxOUc,OjF\|M{CwNVU9N2F-
A549	NF;3dItEgXSxdH;4bYNqfHliYYPzZZk>		NFnHcXE3KGSjeYO=	NEDZSY1EgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBCPTR7IHPlcIx{KGGodHXyJFYh\GG7czDifUBUWkJiYYPzZZktKEmFNUCgQUAxNjF4IN88UU4>	NHPQU\|A9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MUOzNFAyPSd-MkGzN\|AxOTV:L3G+
HCT116	M3n4VmN6fG:2b4jpZ4l1gSCjc4PhfS=>		NIf1TZI3KGSjeYO=	NY\Gb5lzS3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hUEOWMUG2JINmdGy\|IHHmeIVzKDZiZHH5d{BjgSCVUlKgZZN{[XluIFnDOVAhRSByLkG2JO69VS5?	MUi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOTN\|MECxOUc,OjF\|M{CwNVU9N2F-
SNU638	NUXmNos4S3m2b4TvfIlkcXS7IHHzd4F6		NV3a[nhSPiCmYYnz	M17sdmN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJHNPXTZ\|ODDj[YxteyCjZoTldkA3KGSjeYOgZpkhW1KEIHHzd4F6NCCLQ{WwJF0hOC5zNjFOwG0v	MlrCQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjF\|M{CwNVUoRjJzM{OwNFE2RC:jPh?=
MCF7	NWHJRYdySW62aYT1cY9zKGG\|c3H5	NIXObpYyOCC3TR?=	NYLZdGtRPiCmYYnz	NGq3WmJCdnSrdIXtc5Ih[WO2aY\peJkh[WejaX7zeEBpfW2jbjDNR2Y4KGOnbHzzJIF1KDFyIIXNJIFnfGW{IE[g[IF6eyCkeTDTVmIh[XO\|YYmsJGlEPTBiPTCwMlY5KM7:TT6=	NUL1c5h7RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkGzN\|AxOTVpPkKxN\|MxODF3PD;hQi=>
K562	M1XTe2N6fG:2b4jpZ4l1gSCjc4PhfS=>		NEjUXWQ3KGSjeYO=	NEPDOVlEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBMPTZ{IHPlcIx{KGGodHXyJFYh\GG7czDifUBUWkJiYYPzZZktKEmFNUCgQUAzOCEQvF2u	M{TvSVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJzM{OwNFE2Lz5{MUOzNFAyPTxxYU6=
A2780	M4\DXWN6fG:2b4jpZ4l1gSCjc4PhfS=>		MmK4O\|IhcHK\|	NGLPbWZEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBCOjd6MDDj[YxteyCjZoTldkA4OiCqcoOgZpkhW1KEIHHzd4F6NCCLQ{WwJF0hOC5yMEGg{txONg>?	MoPPQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN4MUe3PFQoRjJ\|NkG3O\|g1RC:jPh?=
NYH	MXnDfZRwfG:6aXPpeJkh[XO\|YYm=		M2DBe\|Mhf2Wna4O=	MX;DfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDOXWgh[2WubIOgZYZ1\XJiMzD3[YVseyCkeTDjcI9vd2enbnnjJJN2en[rdnHsJIF{e2G7LDDMSFUxKD1iMD6wNFE2KM7:TT6=	M2D6OFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|Nke5PVE2Lz5{M{[3PVkyPTxxYU6=
K562	NUPqVIJCS3m2b4TvfIlkcXS7IHHzd4F6		NXfKUJdOQTZiaILz	NF3nO2pEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBMPTZ{IHPlcIx{KGGodHXyJFk3KGi{czDifUBOXFRiYYPzZZktKEmFNUCgQUAxNjByN{Kg{txONg>?	NEjTc4k9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{[3PVkyPSd-MkO2O\|k6OTV:L3G+
A2780	NYTIfFAzSW62aYDyc4xq\mW{YYTpeoUh[XO\|YYm=		NE\yNYc4OiCqcoO=	MWjBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKEF{N{iwJINmdGy\|IHHzd4V{e2WmIHHzJIdzd3e2aDDpcohq[mm2aX;uJIFnfGW{IEeyJIhzeyCkeTDTVmIu[mG\|ZXSgcYlkem:ybHH0[UBz\WGmZYKgZY5idHm\|aYOsJGlEPTBiPTCwMlAxOSEQvF2u	NIX3OXU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{i1PVEyQCd-MkO4OVkyOTh:L3G+
NYH	MlLDR5l1d3SxeHnjbZR6KGG\|c3H5			NVLEU4YxS3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hVlmKIHPlcIx{KGK7IHPsc45w\2WwaXOgZZN{[XluIFnDOVAhRSByLkCwNVUh\|ryPLh?=	NWnrWIEzRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkSxOlQxQDZpPkK0NVY1ODh4PD;hQi=>
A2780	NH;3cmREgXSxdH;4bYNqfHliYYPzZZk>		NIjXTmM4OiCqcoO=	M4DTVmN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJGEzPzhyIHPlcIx{KGG\|c3Xzd4VlKGG\|IHfyc5d1cCCrbnjpZol1cW:wIHHmeIVzKDd{IHjyd{BjgSCZU2StNUBie3OjeTygTWM2OCB;IECuNFAyPiEQvF2u	MWm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDF4NEC4Okc,OjRzNkSwPFY9N2F-
HepG2	MV3GeY5kfGmxbjDhd5NigQ>?		Ml3WNUBpeg>?	M1;uNmlvcGmkaYTpc44hd2ZiTlHNVHQhcW5iaIXtZY4hUGWyR{KgZ4VtdHNidYPpcochYzF2Q22tcolkd3SrbnHtbYRmN1CUUGCgZZMhe3Wkc4TyZZRmKGG\|c3Xzd4VlKGG\|IH\vdo1ifGmxbjDv[kBcOTSFXT3ubYNwfGmwYX3p[IUhdW:wb371Z4xmd3SrZHWgZYZ1\XJiMTDodkBjgSCuaYH1bYQhe2OrboTpcIxifGmxbjDjc5VvfGmwZzDhcoFtgXOrczygTWM2OCB;IECuNFAzOiEQvF2u	NVvsNnV1RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkSxOlQxQDZpPkK0NVY1ODh4PD;hQi=>
PC3	NGX6fVNEgXSxdH;4bYNqfHliYYPzZZk>			NFnCOlBEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBRSzNiY3XscJMh[nliY3zvco9o\W6rYzDhd5NigSxiSVO1NEA:KDBwMECzPEDPxE1w	MV:8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDF4NEC4Okc,OjRzNkSwPFY9N2F-
A2780	MnHsR5l1d3SxeHnjbZR6KGG\|c3H5			NFnOcVFEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBCOjd6MDDj[YxteyCkeTDjcI9vd2enbnnjJIF{e2G7LDDJR\|UxKD1iMD6wNFU4KM7:TT6=	Mkm5QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjRzNkSwPFYoRjJ2MU[0NFg3RC:jPh?=
A431	MmX6R5l1d3SxeHnjbZR6KGG\|c3H5			MYPDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDBOFMyKGOnbHzzJIJ6KGOub37v[4VvcWNiYYPzZZktKEmFNUCgQUAxNjByNkGg{txONg>?	Ml\LQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjRzNkSwPFYoRjJ2MU[0NFg3RC:jPh?=
MCF-7	MVLDfZRwfG:6aXPpeJkh[XO\|YYm=		NGS2NVc4OiCqcoO=	NUS4boM6S3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hVUOILUegZ4VtdHNiYYPz[ZN{\WRiYYOg[5Jwf3SqIHnubIljcXSrb36gZYZ1\XJiN{KgbJJ{KGK7IGfTWE0yKGG\|c3H5MEBKSzVyIE2gNE4xODd2IN88UU4>	NX3PUXM4RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkSxOlQxQDZpPkK0NVY1ODh4PD;hQi=>
MCF7	MXjDfZRwfG:6aXPpeJkh[XO\|YYm=			MkjVR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gUWNHPyClZXzsd{BjgSClbH;uc4dmdmmlIHHzd4F6NCCLQ{WwJF0hOC5yMEi0JO69VS5?	Mk\aQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjRzNkSwPFYoRjJ2MU[0NFg3RC:jPh?=
HCT116	NHnLcmZEgXSxdH;4bYNqfHliYYPzZZk>		NFfpNXQ4OiCqcoO=	NHPJOnBEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBJS1RzMU[gZ4VtdHNiYYPz[ZN{\WRiYYOg[5Jwf3SqIHnubIljcXSrb36gZYZ1\XJiN{KgbJJ{KGK7IGfTWE0yKGG\|c3H5MEBKSzVyIE2gNE4xOTB7IN88UU4>	MYW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDF4NEC4Okc,OjRzNkSwPFY9N2F-
SKOV3	MlXyR5l1d3SxeHnjbZR6KGG\|c3H5			MnS2R5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gV2tQXjNiY3XscJMh[nliY3zvco9o\W6rYzDhd5NigSxiSVO1NEA:KDBwMkGxJO69VS5?	M4H5bVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2MU[0NFg3Lz5{NEG2OFA5PjxxYU6=
HCT116	MkTwR5l1d3SxeHnjbZR6KGG\|c3H5		M33sO\|czKGi{cx?=	MnKyR5l1d3SxeHnjbZR6KGGpYXnud5QhSVCROE[2MZJme2m\|dHHueEBpfW2jbjDIR3QyOTZiY3XscJMh[XO\|ZYPz[YQh[XNiZ4Lve5RpKGmwaHnibZRqd25iYX\0[ZIhPzJiaILzJIJ6KFeVVD2xJIF{e2G7LDDJR\|UxKD1iMD65OFYh\|ryPLh?=	M4[3UFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2MU[0NFg3Lz5{NEG2OFA5PjxxYU6=
A2780	M33GdWFvfGmycn;sbYZmemG2aY\lJIF{e2G7		NYDlOnZGPzJiaILz	MVLBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKEF{N{iwJINmdGy\|IHHmeIVzKDd{IHjyd{BjgSC\|dXzmc5Jpd2SjbXnu[UBDKGG\|c3H5MEBKSzVyIE2gNE4xODFizszNMi=>	MVO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDRyNUSxPUc,OjR2MEW0NVk9N2F-
A2780	NV\UU3JGTnWwY4Tpc44h[XO\|YYm=		MknwO\|IhcHK\|	NFnZOGJKdmirYnn0bY9vKG:oIF7BUXBVKGmwIHj1cYFvKEF{N{iwJINmdGy\|IHHzd4V{e2WmIHHzJIRm[3KnYYPlJIlvKGOnbHygeoli[mmuaYT5JIFnfGW{IEeyJIhzeyCkeTDTVmIh[XO\|YYmsJGlEPTBiPTCwMlAxOSEQvF2u	MorHQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjd3NEGyO\|EoRjJ5NUSxNlcyRC:jPh?=
DE3	MlTDSpVv[3Srb36gZZN{[Xl?		MlzwNVUhdWmwcx?=	NF7FWYJKdmirYnn0bY9vKG:oIHj1cYFvKG[3bHygcIVv\3SqIFOteIVzdWmwYXygTIl{Pi22YXfn[YQhVkGPUGSg[ZhxemW\|c3XkJIlvKEW\|Y3jldolkcGmjIHPvcIkhWm:\|ZYT0ZUApTEV\|KTDj[YxteyC3c3nu[{BvcWOxdHnuZY1q\GViYYOgd5Vje3S{YYTlJIlv[3WkYYTl[EBnd3JiMUWgcYlveyCycnnvdkB1dyC\|dXLzeJJifGViYXTkbZRqd25ibXXhd5Vz\WRiYX\0[ZIhOzBibXnud{BqdiCycnXz[Y5k\SCxZjDQVnBRNCCLQ{WwJF0hOC5yMEOg{txONg>?	NHTVZ4Q9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{N{W0NVI4OSd-Mke1OFEzPzF:L3G+
SH-SY5Y	NHnY[nREgXSxdH;4bYNqfHliYYPzZZk>		MXu1OkBpenN?	NXPw[ZJrS3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hW0hvU2m1XUBk\WyuczDhd5Nme3OnZDDhd{Bz\WS3Y4Tpc44hcW5iY3XscEB3cWGkaXzpeJkh[W[2ZYKgOVYhcHK\|IHL5JG1VXCCjc4PhfUwhTUN3MDC9JFAvODB\|NDFOwG0v	M3nGUFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ6MU[1O\|QzLz5{OEG2OVc1OjxxYU6=
A2780	MojGR5l1d3SxeHnjbZR6KGG\|c3H5			NI\OT3BEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBCOjd6MDDj[YxteyCjc4Pld5Nm\CCjczDy[YR2[3Srb36gbY4h[2WubDD2bYFjcWyrdImsJGlEPTBiPTCwMlAxPDJizszNMi=>	M3jTdVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ6MU[1O\|QzLz5{OEG2OVc1OjxxYU6=
PC3	NUPvNFNnSW62aYDyc4xq\mW{YYTpeoUh[XO\|YYm=		MYe1JIRigXN?	NI\hfo1CdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIGDDN{Bk\WyuczDhd5Nme3OnZDDhd{Bz\WS3Y4Tpc44hcW5iY3XscEB3cWGkaXzpeJkhcW6ldXLheIVlKG[xcjC1JIRigXNiYomgR4VtdC22aYTldkBIdG9icnXh[4VvfCCkYYPl[EBie3OjeTygTWM2OCB;IECuNFA2PyEQvF2u	NGTpSnQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OE[xNFk5PCd-Mki2NVA6QDR:L3G+
HepG2	NELHcYNEgXSxdH;4bYNqfHliYYPzZZk>		NXPES4tvPzJiaILz	M3LkU2N6fG:2b4jpZ4l1gSCrbjDoeY1idiCKZYDHNkBk\WyuczDhd5Nme3OnZDDhd{Bz\WS3Y4Tpc44hcW5iY3XscEB3cWGkaXzpeJkh[W[2ZYKgO\|IhcHK\|IHL5JG1VXCCjc4PhfUwhUUN3MDC9JFAvQDlizszNMi=>	NFfzXZU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OEi4OVg{PCd-Mki4PFU5OzR:L3G+
MDA-MB-231	NWDxfJh[S3m2b4TvfIlkcXS7IHHzd4F6		MWK3NkBpenN?	MULDfZRwfG:6aXPpeJkhcW5iaIXtZY4hVUSDLV3CMVI{OSClZXzsd{Bie3Onc4Pl[EBieyC{ZXT1Z5Rqd25iaX6gZ4VtdCC4aXHibYxqfHliYX\0[ZIhPzJiaILzJIJ6KE2WVDDhd5NigSxiSVO1NEA:KDFwMzFOwG0v	NXe3VYIzRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMki4PFU5OzRpPkK4PFg2QDN2PD;hQi=>
HCT116	M4rqcWN6fG:2b4jpZ4l1gSCjc4PhfS=>		MXW3NkBpenN?	NETTUGhEgXSxdH;4bYNqfHliaX6gbJVu[W5iSFPUNVE3KGOnbHzzJIF{e2W\|c3XkJIF{KHKnZIXjeIlwdiCrbjDj[YxtKH[rYXLpcIl1gSCjZoTldkA4OiCqcoOgZpkhVVSWIHHzd4F6NCCLQ{WwJF0hOS54IN88UU4>	NEXFUnc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OEi4OVg{PCd-Mki4PFU5OzR:L3G+
HepG2	NVSzfolnS3m2b4TvfIlkcXS7IHHzd4F6		NGroclQ4OiCqcoO=	NXr3SG9oS3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hUGWyR{KgZ4VtdHNiYYPz[ZN{\WRiYYOgbY5pcWKrdHnvckBw\iClZXzsJIdzd3e2aDDh[pRmeiB5MjDodpMh[nliTWTUJIF{e2G7LDDJR\|UxKD1iMD64PUDPxE1w	MVW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTN2OEiwPEc,Ojl\|NEi4NFg9N2F-
HCT116	NUK5XXIzS3m2b4TvfIlkcXS7IHHzd4F6		NXXHdIhCPzJiaILz	MonlR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gTGNVOTF4IHPlcIx{KGG\|c3Xzd4VlKGG\|IHnubIljcXSrb36gc4Yh[2WubDDndo94fGhiYX\0[ZIhPzJiaILzJIJ6KE2WVDDhd5NigSxiSVO1NEA:KDFwNjFOwG0v	M1\oclxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7M{S4PFA5Lz5{OUO0PFgxQDxxYU6=
A549	NFnsSHREgXSxdH;4bYNqfHliYYPzZZk>		MXm3NkBpenN?	NXmzWGd3S3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hSTV2OTDj[YxteyCjc4Pld5Nm\CCjczDpcohq[mm2aX;uJI9nKGOnbHyg[5Jwf3SqIHHmeIVzKDd{IHjyd{BjgSCPVGSgZZN{[XluIFnDOVAhRSB\|Lkeg{txONg>?	M3mxOVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7M{S4PFA5Lz5{OUO0PFgxQDxxYU6=
SH-SY5Y	NXnXOWdtSXW2b4DoZYd6KGG\|c3H5		M3HkTlQxKGi{cx?=	M{\mV2lv\HWldHnvckBw\iCjdYTvdIhi\3liaX6gbJVu[W5iU1itV3k2YSClZXzsd{Bie3Onc4Pl[EBieyCOQ{OvdIhwe3Cqb4Tp[Jlt\XSqYX7vcIFucW6nIHPveZBtcW6pIHHmeIVzKDRyIHjyd{BjgSCZZYP0[ZJvKGKub4SgZY5idHm\|aYO=	NW\hRVRxRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUm5OlEyQDNpPkG5PVYyOTh\|PD;hQi=>
MCF7	NG\xU\|RCdnSrdIXtc5Ih[XO\|YYm=		NFnpSmI3KGSjeYO=	MmTBRY51cXS3bX;yJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iTVPGO{Bk\WyuczDh[pRmeiB4IHThfZMh[nliU2LCJIF{e2G7	NHTxcog9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MUOzNFAyPSd-MkGzN\|AxOTV:L3G+
MDCK	MnjISpVv[3Srb36gZZN{[Xl?	NVjxNo96OTBidV2=		MVPBdJBiemWwdDDw[ZJu\WGkaXzpeJkh[WO{b4PzJIFxcWOjbDD0c{Bj[XOxbHH0[ZJidCC\|aXTlJIlvKGSxZzDNSGNMKGOnbHzzJIF1KDFyIIXNJIJ6KEyFLV3TM21UKGGwYXz5d4l{	NUD2TIRbRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO4OVkyOThpPkKzPFU6OTF6PD;hQi=>
DU145	MnnyR5l1d3SxeHnjbZR6KGG\|c3H5			NFLz[2NEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBFXTF2NTDj[YxteyCkeTDjcI9vd2enbnnjJIF{e2G7	M{K2flxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2MU[0NFg3Lz5{NEG2OFA5PjxxYU6=
MCF7	MorkR5l1d3SxeHnjbZR6KGG\|c3H5		MWm5OkBpenN?	NV;CZoRnS3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hVUOINzDj[YxteyCjZoTldkA6PiCqcoOgZpkh[2yxbn;n[Y5q[yCjc4PhfS=>	M1z5cFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2MU[0NFg3Lz5{NEG2OFA5PjxxYU6=
HCT116	M4DBZ2Z2dmO2aX;uJIF{e2G7			NWHGdZR2WmW\|aYP0ZY5k\SCoYXP0c5ItKHKjdHnvJI9nKEmFNUCg[o9zKEGST{i2Ok1z\XOrc4ThcpQhcHWvYX6gTGNVOTF4IHPlcIx{KHSxIFnDOVAh\m:{IHj1cYFvKEiFVEGxOkBk\Wyucx?=	MXm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDF4NEC4Okc,OjRzNkSwPFY9N2F-
A2780	NXGzeIhwSW62aYDyc4xq\mW{YYTpeoUh[XO\|YYm=		M2TvWFczKGi{cx?=	NGLaUodCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIFGyO\|gxKGOnbHzzJIFnfGW{IEeyJIhzeyCkeTDzeYxnd3Kqb3ThcYlv\SCEIHHzd4F6KGmwIIDy[ZNmdmOnIH;mJI5q[2:2aX7hcYll\SCvb37vcpVkdGWxdHnk[S=>	NGfQfW49[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NESwOVQyQSd-MkS0NFU1OTl:L3G+
Sf9	MkjkSpVv[3Srb36gZZN{[Xl?		MnrmN\|AhdWmwcx?=	M2jOV2lvcGmkaYTpc44hd2ZicnXjc41jcW6jboSg[pVtdCCuZX7neIghcHWvYX6gR{11\XKvaX7hcEBJcXNxZnzh[{11[WepZXSgTGRCSzFiZYjwdoV{e2WmIHnuJIJi[3Wub4\pdpV{KGmwZnXjeIVlKFOoOTDpcpNm[3RiY3XscJMh[W[2ZYKgN\|AhdWmwczDifUBndHWxcnXzZ4Vv[2ViYYPzZZk>	NI\FNZI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUO0PFgxQCd-MkmzOFg5ODh:L3G+

... Click to View More Cell Line Experimental Data

Assay

Methods	Test Index	PMID
Western blot	SIRT1; PubMed: 29905535 Aging (Albany NY) Human retinal pigment epithelial cells (ARPE-19) were treated with different doses (0.01-10μM) of FK866 and expression of SIRT1 was evaluated by western blotting. p-AMPK / AMPK / p-EIF2A / EIF2A / p-4EBP1 / 4EBP1; PubMed: 29541451 Cancer Metab CEM PA cells were treated with 5 and 100 nM FK866 for 48 h. Western blot showing expression of AMPK, mTOR, 4EBP1, and EIF2A in CEM PA cells. AKT / pAKT(Ser-473) / mTOR / p-mTOR(Ser-2448); PubMed: 26542945 BMC Cancer Jurkat cells were treated for 48 h with or without (Mock) the indicated concentration of FK866. Thereafter, cells were lysed and the levels of total and p-Akt (Ser-473), total and p-MTOR (Ser-2448), total and p-4EBP1 (Ser-65 and Thr-70).	29905535 29541451 26542945
Immunofluorescence	pMLKL; PubMed: 29996103 Cell Rep Immunofluorescence for pMLKL (monoclonal pMLKL antibody, red, phospho S358) and nuclei (DAPI, blue) in THP-1 cells treated with the indicated concentrations of FK866 for 6 hr. Scale bars, 10 μm. phGSK3β; PubMed: 22207684 Haematologica Representative DUOLINK images of phospho-GSK3β (Ser9) protein expression in HL60 cells treated with 10 nM of FK866 for 96 h or 100 nM of AC93253 for 48 h, or with DMSO as a control. ph-β-catenin ; PubMed: 22207684 Haematologica Representative images of inactive phospho-β-catenin (Ser33/37) protein expression in HL60 cells treated with 10 nM of FK866, 100 nM of AC93253 or DMSO as a control	29996103 22207684
Growth inhibition assay	Cell viability ; PubMed: 27462772 Oncotarget Twenty-three PDAC-derived PCCs were treated for 72 h with increasing concentrations of FK866 ranging from 0 to 1000 nM. The horizontal dotted line indicates 50% cell viability. PCCs with the highest sensitivity are highlighted by a blue line and those wit䲧疝Ỵ疞㧀疜膉痘 瘿�෋ᾰƌ	27462772

In vivo

APO866 administered intraperitoneally at dose of 20 mg/kg twice a day for 4 days, repeat weekly over 3 weeks, prevents and abrogats tumor growth in C.B.-17 SCID mice xenograft models of human AML, lymphoblastic lymphoma, and leukemia. ^[1] APO866 at dose of 0.12 mg/kg/hour prevents joint destruction and leukocyte infiltration through inhibition of PBEF in mice with CIA. ^[2]

Protocol

Cell Research:

^[1]

- Collapse

Cell lines: 41 hematologic malignant cell lines
Concentrations: 0 - 10 nM
Incubation Time: 72 hours or 96 hours
Method:
For MTT assays, 0.5 × 10⁶ cells/mL is plated in triplicate on 96-well plates. APO866 (0.01 nM-100 nM) is added in 50 μL of culture medium, with culture medium alone serving as control. After 72 or 96 hours of incubation, 15 μL of dye solution is added to each well and cells are incubated for an additional 4 hours. Stop solution (100 μL/well) is added for 1 hour and the absorbance is read at 570 nm on a spectrophotometer. For trypan blue dye exclusion staining, 0.5 × 10⁵ cells/well is grown in 6-well plates with 1 mL media in the absence or presence of APO866 for 96 hours. Cells from each sample are incubated with 10 μL trypan blue solution (at a 1:1 ratio [vol/vol] for 1 minute). Cell survival is determined by calculating proportion of live (unstained) cells.

(Only for Reference)

Animal Research:

^[1]

- Collapse

Animal Models: C.B.-17 SCID mice xenograft models of human AML, lymphoblastic lymphoma, and leukemia.
Dosages: 20 mg/kg
Administration: administered intraperitoneally twice a day for 4 days, repeated weekly over 3 weeks
(Only for Reference)

References

- Collapse

Solubility (25°C)

In vitro	Ethanol	78 mg/mL (199.22 mM)
	DMSO	Insoluble
	Water	Insoluble
In vivo	Add solvents to the product individually and in order(Data is from Selleck tests instead of citations): 5% DMSO+40% PEG 300+5% Tween 80+50% ddH2O For best results, use promptly after mixing.	4mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information Download Daporinad (FK866, APO866) SDF

Molecular Weight	391.51
Formula	C₂₄H₂₉N₃O₂
CAS No.	658084-64-1
Storage	3 years-20°C powder 2 years-80°C in solvent
Synonyms	N/A
Smiles	C1CN(CCC1CCCCNC(=O)C=CC2=CN=CC=C2)C(=O)C3=CC=CC=C3

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

Dosage

mg/kg

Average weight of animals

Dosing volume per animal

Number of animals

Step 2: Enter the in vivo formulation (Different batches have different solubility ratios, please contact Selleck to provide you with the correct ratio)

% DMSO+ % + % Tween 80+ % ddH₂O

Calculate Reset

Calculation results:

Working concentration： mg/ml；

Method for preparing DMSO master liquid: ： mg drug pre-dissolved in μL DMSO (Master liquid concentration mg/mL， Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation：Take μL DMSO master liquid, next addμL PEG300， mix and clarify, next addμL Tween 80，mix and clarify, next add μL ddH₂O，mix and clarify.

Note：1.Please make sure the liquid is clear before adding the next solvent.
2.Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.

Bio Calculators

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

Serial Dilutions
Concertration (start):
Dilution-folds:

Computed Result

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

Frequently Asked Questions

Question 1:
We are considering the use of S2799 for in vivo injections, Any suggestions for the formula?
Answer:
The vehicle we recommend for S2799 in vivo study is 45% Propylene glycol (dissolve first) +5% Tween 80+ddH2O. You can dissolve the compound in Propylene glycol first and then dilute with water with Tween 80. The solution is clear and can be used for injection.

Choose Your Country or Region

By Signaling Pathways

By product type

Daporinad (FK866, APO866)